Kilitch Drugs (India) (NSE:KILITCH) EV-to-FCF: (As of Jul. 09, 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
85 GF Score
Price ₹183.12
GF Value ₹226.20
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kilitch Drugs (India)'s Enterprise Value is ₹6,526 Mil. Kilitch Drugs (India)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Kilitch Drugs (India)'s EV-to-FCF for today is .

The historical rank and industry rank for Kilitch Drugs (India)'s EV-to-FCF or its related term are showing as below:

NSE:KILITCH' s EV-to-FCF Range Over the Past 10 Years
Min: -8.99   Med: 0   Max: 0
Current: -8.99

NSE:KILITCH's EV-to-FCF is ranked worse than
100% of 563 companies
in the Drug Manufacturers industry
Industry Median: 20.77 vs NSE:KILITCH: -8.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-09), Kilitch Drugs (India)'s stock price is ₹183.12. Kilitch Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8.895. Therefore, Kilitch Drugs (India)'s PE Ratio (TTM) for today is 20.59.


Kilitch Drugs (India)  (NSE:KILITCH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kilitch Drugs (India)'s PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=183.12/8.895
=20.59

Kilitch Drugs (India)'s share price for today is ₹183.12.
Kilitch Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.895.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kilitch Drugs (India) EV-to-FCF Related Terms


Kilitch Drugs (India) EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) EV-to-FCF Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -93.31 -146.40 -73.76 -19.42 -6.13

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.42 0.00 0.00 0.00 -6.13

NSE:KILITCH vs ZTS, UTHR: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kilitch Drugs (India) EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kilitch Drugs (India)'s EV-to-FCF falls into.


NSE:KILITCH
85GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) EV-to-FCF Calculation

Kilitch Drugs (India)'s EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6525.776/0
=

Kilitch Drugs (India)'s current Enterprise Value is ₹6,526 Mil.
Kilitch Drugs (India)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹183.12 is trading 19% below its estimated GF Value™ of ₹226.20. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • EV-to-FCF:
  • GF Value™: ₹226.20 vs. price of ₹183.12 (19% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
85GF Score

Get the complete analysis for NSE:KILITCH

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹183.12
Price
₹226.20
GF Value